2026 年至 2032 年肌少症治療市場（依治療類型、給藥途徑、最終使用者和地區分類）

2026-2032 年肌少症治療市場評估

肌少症是一種導致肌肉質量和力量下降的疾病，嚴重影響老年人的生活品質。隨著人口老化，人們對肌少症的不良健康影響以及早期發現和管理的重要性的認知不斷提高，這推動了對有效治療方法和干涉措施的需求。根據 Verified Market Research 分析師預測，肌少症治療市場規模將從 2024 年的約 2.8946 億美元下降至預測期內的 4.4423 億美元。

此外，持續的研究和開發努力正在推動新治療方法，醫療保健專業人員和患者對這種與老齡化相關的疾病的有效治療方法的需求正在加速市場擴張，預計從 2026 年到 2032 年，複合年成長率將達到 5.5%。

肌少症治療市場定義/概述

肌少症治療包括一系列旨在預防、管理和緩解肌少症的產品和服務。肌少症退化性疾病，其特徵是骨骼肌質量、力量和功能下降，尤其常見於老年人。治療策略可能包括營養干預，例如補充蛋白質、維生素和礦物質，以及阻力訓練和物理治療，以增強力量和功能。治療肌少症可以降低跌倒和骨折的風險，提高運動能力，管理相關的代謝紊亂，支持更健康的老齡化，並維持日常活動的獨立性，從而改善老年人的生活品質。

影響肌少症治療市場成長的市場促進因素有哪些？

全球老齡人口的成長是肌少症治療市場的主要驅動力。根據世界衛生組織 (WHO) 的數據，2015 年至 2050 年期間，全球 60 歲及以上人口的比例將幾乎加倍，從 12% 增加到 22%。到 2050 年，80% 的老年人將生活在中低收入國家。這種人口結構變化至關重要，因為肌少症主要發生在老年人身上。根據國際骨質疏鬆症基金會的數據，肌少症影響約 10% 的 60 歲及以上族群，而 80 歲及以上族群的發生率則上升至 50%。

慢性疾病可導致或加重肌少症，進而增加治療需求。根據美國美國10 人中就有 6 人患有至少一種慢性疾病，每 10 人中就有 4 人患有兩種或兩種以上的慢性疾病。糖尿病影響全球約 4.63 億成年人，它會加速肌肉流失。研究表明，2 型糖尿病患者的肌少症發生率比非糖尿病患者高 15%。

此外，醫療保健專業人員意識的不斷提升以及更先進診斷工具的開發，也推動了肌少症治療市場的發展。 2018年，歐洲老年人肌少症工作小組 (EWGSOP) 修訂了肌少症的定義和診斷標準，從而提高了診斷的準確性。根據發表在《惡病質、肌少症和肌肉》雜誌上的一項研究，當使用更新的 EWGSOP2 標準替代原標準時，肌少症的盛行率從 12.9% 上升至 17.7%。這項診斷改進預計將增加肌肉減少症治療的需求。

實施肌少症治療的主要挑戰是什麼？

肌少症治療和療法的高昂成本對市場構成了重大挑戰。許多有效的治療方法，例如營養補充劑和專科藥物，價格高昂，因此很大一部分老年人口無法負擔。這種經濟障礙阻礙了患者尋求治療或遵守處方方案，從而降低了肌少症治療的整體效果，並限制了市場擴張。

此外，與老齡化相關的社會觀念和污名化也構成了治療的障礙。許多人由於對老齡化的誤解以及認為肌肉流失是老化不可避免的一部分而不願尋求肌肉減少症的治療。這導致人們對治療肌少症的必要性缺乏認知，從而導致診斷不足和治療不足，限制了市場的成長潛力。

目錄

第1章 引言

• 市場定義
• 市場區隔
• 調查方法

第2章執行摘要

• 主要發現
• 市場概覽
• 市場亮點

第3章市場概述

• 市場規模和成長潛力
• 市場趨勢
• 市場促進因素
• 市場限制
• 市場機會
• 波特五力分析

第4章 肌少症治療市場（依治療類型）

• 蛋白質補充劑
• 維生素B12補充劑
• 維生素 D 和鈣補充劑
• 其他

第5章 肌少症治療市場（依給藥途徑）

• 口服
• 注射
• 其他

第6章 肌少症治療市場（依最終使用者分類）

• 醫院
• 藥局和零售藥局
• 網路藥局

第7章區域分析

• 北美洲
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 英國
• 德國
• 法國
• 義大利
• 亞太地區
• 中國
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中東和非洲
• 南非
• 沙烏地阿拉伯
• 阿拉伯聯合大公國

第8章市場動態

• 市場促進因素
• 市場限制
• 市場機會
• COVID-19 市場影響

第9章 競爭態勢

• 主要企業
• 市場佔有率分析

第10章 公司簡介

• Nestle Health Science
• Sanofi SA
• Bayer AG
• Haleon Group of Companies
• Novartis AG
• Abbott Laboratories
• Metagenics LLC
• Pfizer Inc.
• GlaxoSmithKline plc.
• Makers Nutrition LLC

第11章 市場展望與機會

• 新興技術
• 未來市場趨勢
• 投資機會

第12章 附錄

• 簡稱列表
• 來源和參考文獻

Sarcopenia Treatment Market Valuation - 2026-2032

The world's aging population is the main factor driving the sarcopenia treatment market since it raises the prevalence of the ailment, which lowers muscle mass and strength and has a serious negative impact on the quality of life for the elderly. As more people age, the demand for effective therapies and interventions grows, driven by increased knowledge of sarcopenia's negative health impacts and the importance of early detection and management. According to the analyst from Verified Market Research, the sarcopenia treatment market is estimated to reach a valuation of USD 444.23 Million over the forecast subjugating around USD 289.46 Million valued in 2024.

Furthermore, continuing research and development efforts are yielding new therapeutic alternatives, accelerating market expansion as healthcare practitioners and patients seek effective treatments for this age-related illness. It enables the market to grow at a CAGR of 5.5% from 2026 to 2032.

Sarcopenia Treatment Market: Definition/Overview

Sarcopenia treatment includes a variety of products and services aimed at preventing, managing, or alleviating sarcopenia, a degenerative disorder characterized by the loss of skeletal muscle mass, strength, and function, especially in older persons. Treatment strategies include nutritional interventions, such as protein, vitamin, and mineral supplements, as well as resistance training and physical therapies to improve muscular strength and functionality. Sarcopenia treatment can improve the quality of life for the aged by lowering the risk of falls and fractures, increasing mobility, managing associated metabolic disorders, supporting healthier aging, and preserving independence in everyday activities.

What are the Drivers Influencing the Growth of the Sarcopenia Treatment Market?

The growing older population worldwide is a major driver of the sarcopenia treatment market. According to the World Health Organization (WHO), the proportion of the global population over the age of 60 will nearly double between 2015 and 2050, from 12% to 22%. By 2050, 80% of the elderly will live in low- and middle-income countries. This demographic shift is critical since sarcopenia primarily affects elderly people. According to the International Osteoporosis Foundation, sarcopenia affects about 10% of those over the age of 60, with the frequency increasing to 50% in those over the age of 80.

Chronic conditions lead to or aggravate sarcopenia, increasing the need for treatment. According to the Centers for Disease Control and Prevention (CDC), 6 in 10 persons in the United States have at least one chronic disease, with 4 in 10 having two or more. Diabetes, which affects around 463 million adults globally, can speed up muscle loss. Sarcopenia is 15% more common in persons with type 2 diabetes than in those without the disease, according to studies.

Furthermore, the growing awareness among healthcare professionals and the development of better diagnostic tools are propelling the sarcopenia treatment market. In 2018, the European Working Group on Sarcopenia in Older People (EWGSOP) modified its definition and diagnostic criteria for sarcopenia, resulting in more accurate identification of the condition. According to a study published in the Journal of Cachexia, Sarcopenia and Muscle, the prevalence of sarcopenia increased from 12.9% to 17.7% when the updated EWGSOP2 criteria were used instead of the original criteria. This enhanced diagnosis is projected to increase the demand for sarcopenia treatments.

What are the Key Challenges Associated with Adopting Sarcopenia Treatment?

The high expense of sarcopenia treatment and therapies presents a significant challenge for the market. Many effective therapies, such as nutritional supplements and specialist pharmaceuticals, are prohibitively expensive, making them inaccessible to a large percentage of the senior population. This financial barrier discouraged patients from seeking treatment or sticking to prescribed regimens, reducing the overall effectiveness of sarcopenia care and restricting market expansion.

Furthermore, social beliefs and stigmas associated with aging serve as a barrier to treatment. Many people are hesitant to seek treatment for sarcopenia because of misconceptions about aging and the belief that muscle loss is an unavoidable part of growing older. This hesitation leads to underdiagnosis and undertreatment, as those affected fail to grasp the need to tackle sarcopenia, limiting the market's growth potential.

Category-wise Acumens

How Does the Dominance of the Vitamin D & Calcium Supplements Segment Propel the Market?

According to VMR analyst, the vitamin D & calcium supplement segment is anticipated to dominate the segment within the sarcopenia treatment market during the forecast period. The importance of Vitamin D in muscular health adds greatly to the segment's prominence. Vitamin D is required for calcium absorption and bone metabolism, which are critical for muscular function. According to research, adequate levels of Vitamin D can help minimize the incidence of sarcopenia, especially in older persons, resulting in growing demand for these supplements as muscle loss prevention strategies.

The increasing knowledge of sarcopenia's negative effects on health is another driver of the market. As more people become aware of the problems connected with muscle loss, there is a greater emphasis on nutritional solutions to counteract the condition. Vitamin D and calcium supplements are highlighted in educational efforts directed at older persons, driving their usage as part of a proactive strategy to preserve muscle strength and overall health.

Furthermore, the rising prevalence of Vitamin D deficiency among the elderly is a major factor driving demand for Vitamin D and calcium supplements. Many older persons have low Vitamin D levels because of restricted sun exposure and nutritional intake, so supplementation is an important technique for preventing sarcopenia. The increased knowledge of deficiency-related hazards has resulted in a spike in demand for these specific supplements as effective treatment options.

How does the Increasing Hospitalization Rates Contribute to the Demand for Hospitals?

The hospital segment is estimated to hold the largest share of the sarcopenia treatment market during the forecast period. The rising hospitalization rates of elderly people experiencing problems from sarcopenia are a major contributing factor. As the population ages, more people may need medical attention for falls, fractures, and other muscle-related health concerns. Hospitals have an important role in delivering complete care, including diagnosis, treatment, and rehabilitation, which increases the demand for sarcopenia treatments in these settings.

Hospitals' domination is further aided by the availability of specialized healthcare professionals and resources. Hospitals have interdisciplinary teams of geriatricians, dietitians, and physical therapists who can work together to meet the complicated needs of sarcopenic patients. This comprehensive strategy improves treatment efficacy and patient outcomes, making hospitals the optimal setting for managing sarcopenia.

Furthermore, insurance coverage and reimbursement policies frequently favor hospital-based therapies, making them more accessible for patients. Many health insurance policies offer better coverage for hospital-administered treatments than those bought from pharmacy stores or online pharmacies. This financial incentive encourages patients to seek therapy in hospitals, reinforcing the hospital segment's dominant position in the sarcopenia treatment market.

Country/Region-wise Acumens

How Does the High Prevalence of Chronic Diseases Associated with Sarcopenia in Asia Pacific Propel the Market?

According to VMR analysis, the Asia Pacific region is estimated to dominate in sarcopenia treatment market during the forecast period. The Asia Pacific area has a high prevalence of chronic diseases related to sarcopenia, which drives the market. According to the International Diabetes Federation, the Western Pacific region (which comprises the majority of East Asia and Oceania) had the highest number of diabetic adults (163 million) in 2019. This number is predicted to increase to 212 million by 2045. Diabetes is known to accelerate muscle loss, with research indicating that the prevalence of sarcopenia in Asian people with type 2 diabetes is approximately 14.8%, which is much greater than in non-diabetic persons.

Furthermore, the growing healthcare spending and improved diagnostic capabilities in the Asia Pacific region are propelling the sarcopenia treatment market. According to the World Bank, health spending per capita in East Asia and the Pacific rose from $571 in 2010 to $937 in 2019, showing a growing investment in healthcare. In China, one of the region's largest marketplaces, health spending per capita has more than doubled, from $289 in 2010 to $731 in 2019. This increased funding allows for better detection and treatment of illnesses such as sarcopenia.

What are the Drivers Bolstering the Sarcopenia Treatment Market in North America?

North America is estimated to exhibit substantial growth within the market during the forecast period. North America has a huge and expanding older population, which drives the sarcopenia treatment market. According to the United States Census Bureau, the number of Americans aged 65 and up is expected to nearly double, from 52 million in 2018 to 95 million by 2060. Sarcopenia is highly prevalent in North America. According to a study published in the Journal of Cachexia, Sarcopenia, and Muscle, the prevalence of sarcopenia in the United States varies between 10% and 40% among persons aged 60 and older, depending on the diagnostic criteria utilized. This high frequency indicates a sizable market for sarcopenia treatments.

Furthermore, North America, particularly the United States, has high rates of obesity and accompanying metabolic problems, which are directly tied to sarcopenia. According to the Centers for Disease Control and Prevention (CDC), the obesity prevalence in the United States was 42.4% in 2017-2018. According to data from the National Health and Nutrition Examination Survey (NHANES), the prevalence of sarcopenic obesity among older persons in the United States ranges from 4% to 25%, depending on the definition. The increased incidence of obesity, particularly sarcopenic obesity, is driving the need for comprehensive sarcopenia treatments that target both muscle loss and metabolic health.

Competitive Landscape

The sarcopenia treatment market is competitive, with several significant competitors contending for market share. Large companies are focusing on strategic initiatives such as new product launches, mergers and acquisitions, and research and development efforts to increase their market position.

Some of the prominent players operating in the sarcopenia treatment market include:

Nestle Health Science

Sanofi S.A.

Bayer AG

Haleon Group of Companies

Novartis AG

Abbott Laboratories

Metagenics LLC

Pfizer, Inc.

GlaxoSmithKline plc.

Makers Nutrition LLC

Latest Developments:

In July 2024, Abbott Laboratories launched clinical research to assess the efficacy of its novel protein supplement designed exclusively for sarcopenia sufferers. The study's goal is to examine improvements in muscle strength and functionality among older persons, reinforcing Abbott's emphasis on new solutions to age-related health issues.

In June 2024, Pfizer Inc. announced a collaboration with various academic institutions to enhance sarcopenia research. This collaboration intends to investigate the potential of new pharmacological therapy paired with nutritional interventions, demonstrating Pfizer's commitment to addressing the growing concerns about muscle loss in the elderly population.

Sarcopenia Treatment Market, by Category

Treatment Type:

Protein Supplements

Vitamin B12 Supplements

Vitamin D & Calcium Supplements

Others

Route of Administration:

Oral

Injectable

Others

End-User:

Hospitals

Drug Stores and Retail Pharmacies

Online Pharmacies

Region:

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Sarcopenia Treatment Market, By Treatment Type

• Protein Supplements
• Vitamin B12 Supplements
• Vitamin D & Calcium Supplements
• Others

5. Sarcopenia Treatment Market, By Route of Administration

• Oral
• Injectable
• Others

6. Sarcopenia Treatment Market, By End-User

• Hospitals
• Drug Stores and Retail Pharmacies
• Online Pharmacies

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Nestle Health Science
• Sanofi S.A.
• Bayer AG
• Haleon Group of Companies
• Novartis AG
• Abbott Laboratories
• Metagenics LLC
• Pfizer Inc.
• GlaxoSmithKline plc.
• Makers Nutrition LLC

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References